<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11391">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02958644</url>
  </required_header>
  <id_info>
    <org_study_id>HDonaHelena</org_study_id>
    <nct_id>NCT02958644</nct_id>
  </id_info>
  <brief_title>Effect of Prebiotic Supplement on the Body Mass Index of Participants With Severe Obesity</brief_title>
  <acronym>Prebiotic</acronym>
  <official_title>Effect of Prebiotic Supplement on the Body Mass Index of Participants With Severe Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Dona Helena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Dona Helena</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obese patients have a high level of intestinal microflora imbalance, with serious
      consequences such as loss of digestive function. Potential mediators of intestinal
      microbiota are prebiotics, supplements considered safe because they are naturally contained
      in food and human microbiota. Their use has been studied as new therapeutic approach for the
      regulation of intestinal microbiota in various situations of disease, including severe
      obesity.

      This is a double-blind, placebo-controlled, randomized clinical trial to assess the effect
      of prebiotic supplementation (fructo-oligosaccharide - 12 g / day) on body mass index in
      participants with obesity class III, with follow up of 90 days.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body mass index</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma C-reactive protein</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma LDL-cholesterol</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma HDL-cholesterol</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma triglycerides</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1C</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma insulin</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial blood pressure</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin D</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin B12 (cyanocobalamin)</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary intake questionnaire</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saciety questionnaire</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Obesity Class III</condition>
  <arm_group>
    <arm_group_label>Prebiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prebiotics - 12g / day fructo-oligosaccharide supplemented orally for 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo - maltodextrin 12g /day supplemented orally for 90 days.
The study supplements are packed in identical envelopes containing either 12g of oral powder fructo-oligosaccharide or placebo to be diluted in water. The powder and the solution were identical in appearance, taste, and smell.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Prebiotics</intervention_name>
    <arm_group_label>Prebiotics</arm_group_label>
    <other_name>Fructo-oligosaccharide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obesity class III (body mass index ≥40kg/m2)

        Exclusion Criteria:

          -  Current use of prebiotics or use in the last three months

          -  Intolerance to prebiotics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marilyn G Ferreira, PhD</last_name>
    <phone>+55 47 91029228</phone>
    <email>marilyn.ferreira@ielusc.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Dona Helena</name>
      <address>
        <city>Joinville</city>
        <state>Santa Catarina</state>
        <zip>89204-250</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Micheli Arruda, R.N.</last_name>
      <phone>+554734365500</phone>
      <email>micheli.c@donahelena.com.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Hans Dieter Schmidt</name>
      <address>
        <city>Joinville</city>
        <state>SC</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marilyn G Ferreira, PhD</last_name>
      <phone>+55 47 91029228</phone>
      <email>marilyn.ferreira@ielusc.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Alemão Oswaldo Cruz</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01323-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ricardo Cohen, PhD</last_name>
      <email>ricardo.cohen@haoc.com.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital do Coração</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>04004-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernardete Weber, PhD</last_name>
      <email>bweber@hcor.com.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 7, 2016</lastchanged_date>
  <firstreceived_date>November 4, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Dona Helena</investigator_affiliation>
    <investigator_full_name>Marilyn Gonçalves Ferreira Kuntz</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>prebiotic</keyword>
  <keyword>obesity</keyword>
  <keyword>body mass index</keyword>
  <keyword>microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
